Abstract 375P
Background
To determined survival and prognostic factors for non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) patients treated with surgery followed by concurrent chemoradiotherapy (CCRT) or definitive CCRT (dCCRT), aiming to identify optimal chemotherapy doses.
Methods
This retrospective cohort study reviewed 277 non-NPC HNSCC patients treated with platinum-based CCRT at Rajavithi Hospital between January 1st, 2016 and April 30th, 2021. Clinical features, staging, treatment, and outcomes were collected and analyzed.
Results
Overall, 277 patients were diagnosed as HNSCC; median age: 55.9 years; male: 81.2%; ECOG 0-1: 98.9%. The clinical stage was I-III, IVa, and IVb in 23.8%, 53.4%, and 22.8%, respectively. Cisplatin was used in 39.0%, while carboplatin was used in 61.0%. 53.4% underwent surgery followed by CCRT while 46.6% underwent definitive CCRT. Patients treated with adjuvant CCRT led to significantly longer overall survival (OS) and disease-free survival (DFS) than definitive CCRT (HR: 0.54, p<0.001 for OS; HR: 0.61, p<0.001 for DFS). Higher stage and the presence of pathological risk factors were poor prognostic factors for OS in the adjuvant CCRT group, while higher stage and oral cavity and hypopharynx were associated with poorer OS in the definitive CCRT group. Among the interquartile range of cumulative doses (CDs), the study also found a statistically significant difference in OS and DFS for the dCCRT group with carboplatin at the 2nd Quartile compared to the others (6.75-8.58 AUC) (HR 0.38, 95%CI; 0.17-0.86, p=0.02 and HR 0.41, 95%CI; 0.18-0.91, p=0.03, respectively). There was no significant difference in OS/DFS between patients who received CDs of cisplatin of either less or more than 200 mg/m2 or carboplatin in adjuvant CCRT in all population.
Conclusions
This study showed comparable survival outcomes to historical data. Surgery followed by adjuvant CCRT remains the recommended approach. The CDs of cisplatin or carboplatin did not significantly impact outcomes. A trend towards improved survival with CDs within a specific range requires confirmation in further prospective studies.
Clinical trial identification
6518.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract